A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05741021 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer
NSCLC
PD-1

Interventions

DRUG: F520
DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Shandong New Time Pharmaceutical Co., LTD